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Abstract 
 
Opioid overdose is a growing public health 
emergency in the United States. The antidote 
naloxone must be administered rapidly after opioid 
overdose to prevent death. Bystander or “take-home” 
naloxone programs distribute naloxone to opioid 
users and other community members to increase 
naloxone availability at the time of overdose. 
However, data describing the natural history of take-
home naloxone in the hands of at-risk individuals is 
lacking. To understand patterns of naloxone uptake 
in at-risk users, we developed a smart naloxone kit 
that uses low-energy Bluetooth (BLE) to 
unobtrusively detect the transit of naloxone through a 
hospital campus. In this paper, we describe 
development of the smart naloxone kit and results 
from the first 10 participants in our pilot study. 
 
 
1. Introduction  
 
Heroin overdose deaths have more than doubled 
from 2000 to 2014, triggering the growth of harm-
reduction programs aimed at 1) training non-medical 
personnel to recognize and respond to opioid 
overdoses, and 2) dispensing overdose rescue kits 
containing naloxone, the antidote for opioid 
overdose, to at-risk individuals and their friends and 
family from community and emergency department 
sites.[3,6,9,12,15] Despite the growth of “bystander” 
naloxone distribution programs and observations of a 
decrease in opioid overdose deaths in communities 
where they have been implemented, overdose deaths 
continue to increase.[16] The Centers for Disease 
Control (CDC) reported 33,091 individuals died from 
opioid overdose in 2015, a 15.6% increase since 
2014.[13] Unfortunately, rigorous data delineating 
what happens to these overdose rescue kits once 
distributed to heroin users are lacking. Understanding 
the patterns of naloxone distribution and use in a 
community through advanced technology-based 
monitoring can guide strategies to improve naloxone 
distribution programs.[8]  
The introduction of a technology-based 
monitoring system that can easily integrate into a 
standard overdose rescue kit provides the ability to 
directly ascertain the real-time location of naloxone 
rescue kits. By providing insights into the patterns of 
naloxone distribution and use in a community, these 
technology-enabled naloxone kits can provide 
valuable information on real-world uptake of 
bystander naloxone by active heroin users and help to 
optimize naloxone distribution programs. 
Furthermore, this information can guide the 
development of real-time mobile technology 
interventions for these at-risk populations. 
Discovering the fate of naloxone rescue kits can 
be accomplished through unobtrusive low-energy 
Bluetooth (BLE) technology. Similar to monitoring 
medical equipment or patients as they transit through 
a hospital system, BLE technology incorporated into 
naloxone rescue kits dispensed from an emergency 
department (ED) setting can provide insight into the 
uptake of naloxone kits by heroin users and the 
availability of these kits for use in the 
community.[10,14] 
In this pilot study, we deployed a naloxone 
rescue kit with an integrated BLE beacon (“smart 
naloxone kit”) to help determine the community 
penetrance of ED distributed naloxone. 
 
2. The smart naloxone kit  
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The “smart naloxone kit” consists of a standard 
Food and Drug Administration (FDA)-approved 
intranasal naloxone syringe combined with a BLE 
identification tag. As smart naloxone kits exit the 
emergency department, they enter detection zones of 
strategically placed BLE readers which collect and 
log the transit of smart naloxone kits through specific 
locations on a hospital campus (Figures 1 & 2). Data 
from BLE readers indicate the proportion of smart 
naloxone kits that become available for use in the 
community. 
 
 
 
2.1. Low-energy Bluetooth identification 
beacons 
 
BLE beacons (36mm x 23mm x 4mm) powered 
by an integrated battery actively transmit a pre-
programmed unique identifier code. BLE beacons 
have a battery life of three months. Beacons transmit 
pre-programmed identifiers using 2.4 gigahertz 
(GHz) radiofrequency waves, the same frequency 
employed by most WiFi routers and cordless 
telephones.[5] By using a set 2.4GHz frequency, 
BLE beacons avoid interference from conventional 
medical equipment like intravenous pumps, cardiac 
pacemakers and insulin pumps. 
 
2.2. Low-energy Bluetooth systems do not 
affect biological systems 
 
Theoretical concerns have been raised regarding 
the ability of radiofrequency waves to alter the 
molecular composition and efficacy of 
xenobiotics.[2] We believe this concern is 
unfounded. Studies exposing radiofrequency 
identification (RFID) systems, a similar technology 
to BLE but employing slightly different frequencies, 
have shown no alteration in the stereochemistry or 
molecular composition of xenobiotics.[1,2] 
Additionally, RFID is increasingly utilized in 
pharmaceutical manufacturing, underscoring the 
safety of using this technology near xenobiotics.[7]  
 
 
 
2.3. Low-energy Bluetooth readers 
 
BLE readers, approximately the size of a 
wireless router, serve as a relay station for 
information transmitted by BLE beacons: when a 
BLE beacon enters the detection radius of a BLE 
reader, the beacon transmits pre-recorded data 
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including the specific beacon identification number. 
This information is captured by the BLE reader and 
securely stored on its on-board, encrypted memory. 
The BLE reader also transmits BLE beacon transit 
data to a secure cloud-based interface. BLE readers 
have a detection radius of 20 meters and can 
penetrate clothing and metal, therefore allowing 
detection of smart naloxone kits carried in pockets, 
cars, or buses. The readers are powered by 
rechargeable batteries that last for 24 hours, allowing 
them to be affixed to telephone poles or light posts 
without a grounded power source. The readers are 
housed in locked weatherproof, shockproof casings 
built to military specification (Figure 2). 
 
2.4. BLE reader placement 
 
BLE readers were positioned at strategic 
locations around the hospital campus, corresponding 
to the avenues of pedestrian and vehicular egress that 
patients utilize when they are discharged from the 
ED: the ED registration area, the ambulance bay exit, 
the pedestrian walkway to the bus stop, and the two 
main roads for automobile traffic. These locations 
were chosen to capture participants as they exited the 
hospital campus 1) by walking or driving along the 
main roads, 2) by ambulance, 3) by public transit 
(Figure 3). 
 
 
By selecting BLE readers with adequate range to 
cover major road intersections and power to penetrate 
cars, we can detect the transit of smart naloxone kits 
off of a hospital campus. This approach is highly 
scalable—rapid deployment of BLE readers 
throughout a community in response to an escalating 
heroin epidemic can help public health officials and 
researchers discover hotspots of naloxone as a marker 
for heroin use, and target interventions to these key 
geographic areas.  
 
3. Methods 
 
3.1. Design considerations  
 
The smart naloxone kit was designed to be 
discreet to maximize acceptance by heroin users. 
Placing unobtrusive BLE tags within the carton 
containing the syringe, ampule and nasal atomizer 
ensures the ability to locate smart naloxone kits 
without obvious indicators that kits are being tracked. 
Affixing the monitoring device to a critical 
component such as the naloxone syringe was 
considered to address the scenario where a participant 
might keep the medication and atomizer while 
discarding the box prior to leaving the hospital, but 
this was not done out of concern that it might 
interfere with the efficient delivery of naloxone in an 
emergency situation.  
Similarly, BLE readers were selected because 
they provided the necessary combination of detection 
range and penetrance around metal and human bodies 
(which can interfere with the performance of other 
modalities such as RFID), allowing for the detection 
of tagged kits carried in various ways, including in 
pockets, bags, cars, or buses.  
Additionally, using advanced technology to 
detect devices carried by patients with active drug 
use may pose ethical concerns.[11] The smart 
naloxone kit does not track patients continuously. 
Instead, it utilizes a BLE tag that transmits a unique 6 
character identification code that is detected by a 
compatible BLE reader. Thus, the BLE system does 
not provide continuous location data; rather it 
captures discrete episodes of movement through BLE 
reader detection zones. 
Although the system does not continuously track 
patients, security remains an important consideration. 
Radiofrequency ID systems such as BLE can be 
penetrated through passive eavesdropping, signal 
jamming, or reader tampering.[11] Several methods 
are employed to ensure the security of the BLE 
system. First, BLE utilizes advanced encryption 
technologies, the same standard used by the US 
government.[5] Second, rather than using patient 
identifiers such as name, birthdate, or medical record 
number, the BLE tag utilizes the previously 
mentioned 6 character code to identify itself to a BLE 
reader, minimizing any threat to privacy or 
confidentiality should the BLE system be 
compromised. Third, once detected by the reader, the 
BLE tag identifier is transmitted via secure WiFi or 
cellular hotspot connection to a secure password 
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protected interface; alternatively, if no internet 
connection is available, the BLE tag information is 
stored locally on the reader using encrypted internal 
storage until such a time that an internet connection is 
available. Finally, careful selection of BLE reader 
placement prevents interference from other devices 
utilizing similar radiofrequency transmissions, and 
physical security measures such as locks and cables 
minimize tampering with the devices.  
 
3.2. Technology acquisition and verification 
 
BLE beacons (Visybl AssetBeacons) and readers 
(Visybl CloudNodes) were purchased from the 
manufacturer (Visybl Inc., Germantown, MD, USA). 
Field testing was performed using BLE readers 
positioned around the hospital campus, and BLE 
beacons in various configurations to simulate real-life 
situations in which a smart naloxone kit might be 
carried (e.g. in medication cartons, in shirt and pants 
pockets, inside a moving vehicle). The author (JL) 
carried a BLE beacon through detection zones for all 
readers to ensure reliable signal capture.  
 
3.3. Study design 
 
This was a prospective pilot study utilizing a 
convenience sample of participants presenting to the 
ED with a heroin-related complaint. Participants were 
eligible for the study if they were 18 years of age or 
older, English-speaking, able to provide written 
informed consent, and in possession of a mobile 
phone with text messaging capability. Potential 
subjects were excluded if they were pregnant, 
prisoners or in police custody, or presenting with a 
primary psychiatric complaint.  
Participants were enrolled, provided written 
consent, and underwent a standardized training 
session on using naloxone and the functionality of the 
smart naloxone kit. Consenting participants were 
given a brief training on recognizing signs of heroin 
and opioid overdose in addition to the assembly and 
operation of the smart naloxone kit, in accordance 
with validated methods of naloxone teaching 
(prescribetoprevent.com). Next, participants were 
given an overview of the BLE technology utilized in 
the kit. The individual BLE beacon was activated, 
verified to be operational, and sealed in the naloxone 
kit with double sided tape. Contact information was 
obtained from participants, including personal phone 
number and phone number of a friend or family 
member, to maximize our ability to contact subjects 
for follow up.  
As participants departed from the ED, transit of 
the smart naloxone kit off the hospital campus was 
detected by the BLE readers and accessed by batch 
download using a secure cloud-based interface and 
recorded by study staff.  
Subjects were contacted via text message to 
confirm accuracy of the technology on days 7, 10, 
and 13. If there was no response, subjects were 
contacted via phone call on days 7 and 10. If there 
was no response to these phone calls, then subjects’ 
alternate contacts were called. If no response from 
subjects or alternate contacts at 14 days, the subject 
was considered lost to follow up. 
The primary outcome for this study was 
demonstrating the feasibility of utilizing a BLE 
system to observe the transit of naloxone off a 
hospital campus. Secondary outcomes included 
observing the number of kits leaving the hospital 
campus and whether these kits were utilized by 
participants. 
 
4. Results 
 
During the study period, a total of 102 
individuals presented to the ED with a heroin 
overdose or heroin-related complaint. Of these, 10 
individuals were consented, and no individuals 
declined participation. Ten individuals completed the 
study over the 3-month study period. Median age was 
29 years, ten identified as Caucasian, nine 
participants identified as male, and one participant 
identified as female. Seven presented to the ED after 
a heroin overdose while three presented after a 
heroin-related complaint (Table 1). 
 
Table 1. Participant demographics. OD 
denotes overdose. 
ID Age Sex Race Triage Complaint 
 39 M White Withdrawal sx 
 24 M White OD 
 20 M White OD 
 28 M White OD 
 31 M White Detox 
 29 M White OD 
 29 M White Eval 
 29 M White Heroin OD 
 28 M White OD 
 29 F White OD 
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4.1. Smart naloxone kit uptake and 
distribution 
 
All 10 individuals accepted the smart naloxone 
kit and were trained to recognize signs of an opioid 
overdose and administer naloxone. 70% of smart 
naloxone kits (N=7) were detected by BLE readers 
positioned at egress points from the hospital campus. 
Two of the participants whose smart naloxone kits 
were detected by the ED ambulatory exit reader but 
not by the readers positioned along the egress paths 
reported during follow-up that they carried the smart 
naloxone kit off campus (Figure 4). This was likely 
due to technical errors in which the readers were not 
powered on. Of the four participants we successfully 
contacted, one reported having utilized the smart 
naloxone kit to reverse an opioid overdose.  
Unfortunately, 60% of participants (N=6) were lost to 
follow up.  
 
 
 
5. Discussion 
 
Our data shows that a majority of individuals 
accept and carry ED distributed naloxone off a 
hospital campus and into the community. A majority 
of participants carried the smart naloxone kits with 
them on discharge from the ED, suggesting that 
heroin users recognized the dangers of overdose, 
were willing to carry naloxone, and were willing to 
use smart naloxone kits to inform us about their 
patterns of naloxone uptake. This pilot study 
demonstrates that the smart naloxone kit is an 
acceptable and feasible platform to improve 
understanding of naloxone uptake and ultimately 
acceptance among individuals with active substance 
use.   
Our smart naloxone kits were able to provide 
passively generated evidence of naloxone uptake and 
retention through a hospital campus. This pilot 
provides a template for mini smart naloxone kit 
systems to be deployed in conjunction with new or 
existing naloxone distribution programs to assess the 
actual uptake of naloxone. Expansion of these 
concepts could lead to strategic placement of BLE 
readers around known overdose locations in a city to 
determine if distributed naloxone first moves out of 
the naloxone distribution site and if the distributed 
kits are found in areas with overt overdose.  
Engaging heroin users to understand factors 
leading to acceptance or non-acceptance of advanced 
monitoring devices is essential in the development of 
future iterations of smart naloxone kits.[4] Successful 
deployment of a smart naloxone distribution program 
is likely contingent upon actively involving heroin 
users in their design and providing reassurances that 
privacy (e.g. location data not shared with law 
enforcement) is held paramount. 
 
5.1. Limitations 
 
Although our concept is highly scalable, it has 
several limitations. Our pilot study was aimed at 
assessing feasibility of using BLE to detect naloxone 
as it exits the site of distribution from our ED at a 
single hospital campus. However, this study phase is 
crucial to determining if patients will accept this 
technology and distribute it throughout an urban area. 
Further studies will require municipal participation to 
place BLE readers at additional locations, expanding 
the potential detection of smart naloxone kits in our 
community.  
Regrettably, we were unable to contact six 
participants: phone numbers from five participants 
either were disconnected or were unanswered, and 
one participant was unable to be reached due to 
constraints of his treatment program. 
 
5.2. Future directions 
 
BLE labeled naloxone provides a system that is 
easily and quickly deployable that can be leveraged 
to respond to the rising opioid epidemic across the 
United States. An advantage of utilizing BLE-based 
tracking platform is that Bluetooth technology is 
ubiquitous: nearly all smartphones are equipped with 
Bluetooth radios and can functionally serve as BLE 
readers. Thus, any Bluetooth-enabled mobile phone 
can be set up to detect our smart naloxone kit. This 
“crowdsourcing” of BLE tag detection offers a cost-
effective method to vastly expand the ability to detect 
a smart naloxone kit in an urban environment where 
smartphones are omnipresent.  
 
Page 3257
  
6. Conclusion 
 
A smart naloxone kit comprised of BLE-labeled 
nasal naloxone syringe and strategically placed BLE 
readers can provide insight into natural uptake 
patterns of naloxone among individuals at risk for 
heroin overdose. This information will allow for 
improvement in planning community-based 
interventions to prevent deaths from opioid overdose. 
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